Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Tandem Diabetes Care's Revenue for the
three
months ended in Mar. 2026 was $247 Mil. Tandem Diabetes Care's average Accounts Receivable for the
three
months ended in Mar. 2026 was $153 Mil.
Hence, Tandem Diabetes Care's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.61.
Tandem Diabetes Care (LTS:0M0F) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Tandem Diabetes Care Receivables Turnover Related Terms
Tandem Diabetes Care Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0M0F vs AVNS, IRMD, AORT: Receivables Turnover Comparison
For the Medical Devices subindustry, Tandem Diabetes Care's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care (LTS:0M0F) has a Receivables Turnover of 1.61 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tandem Diabetes Care and its competitors. According to the industry distribution chart, Tandem Diabetes Care ranks #218 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 26.9%.
Is Tandem Diabetes Care's Receivables Turnover too high?
Tandem Diabetes Care's current Receivables Turnover is 1.61. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Tandem Diabetes Care's value of 1.61 is 70.8% below this industry median. Based on the distribution chart, Tandem Diabetes Care ranks #218 out of 811 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Tandem Diabetes Care has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Receivables Turnover compare to AVNS and IRMD?
According to the Medical Devices & Instruments industry distribution chart, Tandem Diabetes Care ranks #218 out of 811 companies for Receivables Turnover. This puts Tandem Diabetes Care in the upper half of its industry. The industry median Receivables Turnover is 5.51. Tandem Diabetes Care's value of 1.61 is 70.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tandem Diabetes Care's current Receivables Turnover of 1.61 is 70.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tandem Diabetes Care and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tandem Diabetes Care's current Receivables Turnover is 1.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.85, compared to a current price of $17.14 — trading 42.6% below its estimated fair value. The current Receivables Turnover is 1.61 and 70.8% below the Medical Devices & Instruments industry median of 5.51. Tandem Diabetes Care's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current Receivables Turnover is 1.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of $17.14 is trading 42.6% below its estimated GF Value™ of $29.85.
GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.
Key valuation signals for LTS:0M0F:
Receivables Turnover: 1.61
GF Value™: $29.85 vs. price of $17.14 (42.6% below fair value)
Industry Position: 70.8% below the Medical Devices & Instruments median (#218 of 811)
No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
68GF Score
Get the complete analysis for LTS:0M0F
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M0F has been successfully added to your 
